



1 [Accept and Expend Grant - Public Health Foundation Enterprises - San Francisco Bay  
2 Clinical Trials Unit - \$211,225]

3 **Resolution retroactively authorizing the San Francisco Department of Public Health to**  
4 **accept and expend a grant in the amount of \$211,225 from Public Health Foundation**  
5 **Enterprises to participate in a program entitled "San Francisco Bay Clinical Trials Unit"**  
6 **for the period of December 1, 2014, through November 30, 2015.**

7  
8 WHEREAS, Public Health Foundation Enterprises is the recipient of a grant award from  
9 National Institutes of Health supporting the San Francisco Bay Clinical Trials Unit grant; and

10 WHEREAS, With a portion of these funds, Public Health Foundation Enterprises has  
11 subcontracted with Department of Public Health (DPH) in the amount of \$211,225 for the  
12 period of December 1, 2014, through November 30, 2015; and

13 WHEREAS, As a condition of receiving the grant funds, Public Health Foundation  
14 Enterprises requires the City to enter into an agreement (Agreement), a copy of which is on  
15 file with the Clerk of the Board of Supervisors in File No. 150741; which is hereby  
16 declared to be a part of this Resolution as if set forth fully herein; and

17 WHEREAS, The purpose of this project will fund staff to be responsible for the overall  
18 scientific leadership of the Clinical Trial Unit and Bridge HIV Congressional Research Service  
19 and will prioritize research efforts. This project will also fund staff to oversee the overall  
20 scientific, operational and administrative aspects of the demonstration project and provide  
21 technical expertise and training; and

22 WHEREAS, The estimated grant amount of \$44,530 is budgeted in the FY2014-2015  
23 Annual Appropriation Ordinance, an additional amount of \$166,695 was awarded from Public  
24 Health Foundation Enterprises, for a total amount of \$211,225 after the AAO already was  
25 approved; and

1           WHEREAS, An Annual Salary Ordinance amendment is not required as the grant  
2 partially reimburses DPH for three existing positions, one Manager VIII (Job Class No. 0943)  
3 at .20 FTE, one Senior Physician Specialist (Job Class No. 2232) at .5514 FTE and one  
4 Supervising Physician Specialist (Job Class No. 2233) at .10 FTE for the period of December  
5 1, 2014, through November 30, 2015; and

6           WHEREAS, A request for retroactive approval is being sought because DPH did not  
7 receive the letter of funding allocation until April 9, 2015, for a project start date of December  
8 1, 2014; and

9           WHEREAS, The budget includes a provision for indirect costs in the amount of  
10 \$32,953; now, therefore, be it


11          RESOLVED, That DPH is hereby authorized to retroactively accept and expend a grant  
12 in the amount of \$211,225 from Public Health Foundation Enterprises; and, be it

13          FURTHER RESOLVED, That DPH is hereby authorized to retroactively accept and  
14 expend the grant funds pursuant to San Francisco Administrative Code section 10.170-1; and,  
15 be it

16          FURTHER RESOLVED, That the Director of Health is authorized to enter into the  
17 Agreement on behalf of the City.


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

RECOMMENDED:




Barbara A. Garcia, MPA  
Director of Health

APPROVED:



Office of the Mayor



Office of the Controller

File Number: \_\_\_\_\_  
(Provided by Clerk of Board of Supervisors)

**Grant Resolution Information Form**  
(Effective July 2011)

Purpose: Accompanies proposed Board of Supervisors resolutions authorizing a Department to accept and expend grant funds.

The following describes the grant referred to in the accompanying resolution:

1. Grant Title: **San Francisco Bay Clinical Trials Unit**

2. Department: **Department of Public Health,  
Population Health Division – HIV Bridge**

3. Contact Person: **Martin Soto** Telephone: **415-437-7029**

4. Grant Approval Status (check one):

Approved by funding agency

Not yet approved

5. Amount of Grant Funding Approved or Applied for: **\$211,225**

6a. Matching Funds Required: **\$0**

b. Source(s) of matching funds (if applicable):

7a. Grant Source Agency: **National Institutes of Health (NIH)**

b. Grant Pass-Through Agency (if applicable): **Public Health Foundation Enterprises (PHFE)**

8. Proposed Grant Project Summary:

**This grant will pay for Dr. Buchbinder to be responsible for the overall scientific leadership of the Clinical Trial Unit (CTU) and Bridge HIV Congressional Research Service (CSR), and will prioritize research efforts. She will lead manuscript development at the site, assisting in research design and analysis, presentation and publication of data. This grant will pay Dr. Liu to be responsible for the overall scientific, operational and administrative aspects of the demonstration project. As the lead investigator of the San Francisco site, he will oversee overall study implementation at this site and will be responsible for study enrollment and retention, data collection, evaluation and reporting of AEs, clinical management of study participants, and quality management. This grant will pay Dr. McFarland to be responsible for providing technical expertise and training for the implementation of RDS among transwomen in Rio de Janeiro, Brazil. He will assist with the formative assessment phase to ensure that the theoretical underpinnings of RDS are met in the study population and context, standardize the procedures for implementation, monitor data quality, and assist with the specialized analyses RDS requires. Dr. McFarland will also coordinate measures and methods with the Brazilian National AIDS Program.**

9. Grant Project Schedule, as allowed in approval documents, or as proposed:

Start-Date: **12/01/2014**

End-Date: **11/30/2015**

10a. Amount budgeted for contractual services: **\$0**

b. Will contractual services be put out to bid? **No, existing services**

c. If so, will contract services help to further the goals of the Department's Local Business Enterprise (LBE) requirements? **N/A**

d. Is this likely to be a one-time or ongoing request for contracting out? **N/A**

11a. Does the budget include indirect costs?

Yes

No

b1. If yes, how much? **\$32,953**

b2. How was the amount calculated? **24.03% of Salaries**

- c1. If no, why are indirect costs not included? N/A  
 Not allowed by granting agency  To maximize use of grant funds on direct services  
 Other (please explain):

c2. If no indirect costs are included, what would have been the indirect costs?

12. Any other significant grant requirements or comments:

**We respectfully request for approval to accept and expend these funds retroactive to December 01, 2014. The Department received the letter of funding allocation on April 09, 2015.  
 Grant Code: HCD119/1500**

**\*\*Disability Access Checklist\*\*\*(Department must forward a copy of all completed Grant Information Forms to the Mayor's Office of Disability)**

13. This Grant is intended for activities at (check all that apply):

- |  |   |  |
|--|---|--|
| <input checked="" type="checkbox"/> Existing Site(s) | <input type="checkbox"/> Existing Structure(s)      | <input type="checkbox"/> Existing Program(s) or Service(s) |
| <input type="checkbox"/> Rehabilitated Site(s)       | <input type="checkbox"/> Rehabilitated Structure(s) | <input type="checkbox"/> New Program(s) or Service(s)      |
| <input type="checkbox"/> New Site(s)                 | <input type="checkbox"/> New Structure(s)           |  |

14. The Departmental ADA Coordinator or the Mayor's Office on Disability have reviewed the proposal and concluded that the project as proposed will be in compliance with the Americans with Disabilities Act and all other Federal, State and local disability rights laws and regulations and will allow the full inclusion of persons with disabilities. These requirements include, but are not limited to:

1. Having staff trained in how to provide reasonable modifications in policies, practices and procedures;
2. Having auxiliary aids and services available in a timely manner in order to ensure communication access;
3. Ensuring that any service areas and related facilities open to the public are architecturally accessible and have been inspected and approved by the DPW Access Compliance Officer or the Mayor's Office on Disability Compliance Officers.

If such access would be technically infeasible, this is described in the comments section below:


Comments:

Departmental ADA Coordinator or Mayor's Office of Disability Reviewer:

Ron Weigelt  
 (Name)

Director of Human Resources and Interim Director, EEO, and Cultural Competency Programs  
 (Title)

Date Reviewed: 5-12-15


  
 (Signature Required)

**Department Head or Designee Approval of Grant Information Form:**

Barbara A. Garcia, MPA  
 (Name)

Director of Health  
 (Title)

Date Reviewed: 5/14/15

  
 (Signature Required)

SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH  
 AIDS Office Research Section  
 San Francisco Bay Clinical Trail Unit  
 December 01, 2014 to November 30, 2015  
 Monthly Expenditure and Projection Report

Dept / Div: HPH-03  
 Fund Group: 2S/CHS/GNC  
 Index Code: HCHVRSRCHGR  
 Grant Code: hcd119  
 Grant Detail: 1500

\$183,500 SALARY CAPS PER NIH GUIDES eff 01.11.15

CATEGORY/LINE ITEM	Annual Salary	30.0% Annual Frin Ben	Total Annual Sal/Frin Ben	% OF TIME	% OF FTE	Monthly Rate	Mth	Salary Budget	Frin Ben Budget	Total Budget	Col
<b>A. PERSONNEL</b>											
1. HIV Bridge Director 2237 5 S. Buchbinder	181,500	54,450	235,950	20.00%	0.200	15,125	12	36,300	10,890	47,190	Budget A
Sr Physican Specialist 2232 5 A. Liu	181,500	54,450	235,950	16.00%	0.160	15,125	12	29,040	8,712	37,752	Budget A
Sr Physican Specialist 2232 5 A. Liu	183,500	55,050	238,550	29.135%	0.291	15,292	12	53,463	16,038	69,501	Budget B
Sr Physican Specialist 2232 5 A. Liu	183,500	55,050	238,550	10.00%	0.100	15,292	8	12,220	3,666	15,886	Budget C
Sr Physican Specialist 2233 5 W. McFarland	183,500	55,050	238,550	10.00%	0.100	15,292	4	6,110	1,833	7,943	Budget C
3 COLA										0	
<b>TOTAL PERSONNEL:</b>	<b>913,500</b>	<b>274,050</b>	<b>1,187,550</b>		<b>0.851</b>			<b>137,133</b>	<b>41,139</b>	<b>178,272</b>	
00101 SALARIES:										137,133	
00103 MANDATORY FRINGE:										41,139	
<b>TOTAL PERSONNEL:</b>										<b>178,272</b>	
<b>C. TRAVEL</b>											
1. Local Travel (02301)										0	
2. Out-of-Jurisdiction Travel(02101)										0	
Sub Total TRAVEL										<u>0</u>	
<b>D. EQUIPMENT</b>											
1.										0	
Sub Total EQUIPMENT										<u>0</u>	
<b>E. MATERIALS AND SUPPLIES</b>											
1.										0	
Sub Total SUPPLIES										<u>0</u>	
<b>F. CONTRACTUAL SERVICES (02789)</b>											
1.										0	
Sub Total CONTRACTS										<u>0</u>	
<b>G. OTHER</b>											
1. Rent Paid to RE (081RS)										0	
2. IS/TIS/ISD Svcs (081CS)										0	
3 IS/TIS/ISD Svcs (081CS)										0	
Sub TOTAL OTHER										<u>0</u>	
<b>TOTAL DIRECT COST</b>										<b>178,272</b>	

SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH  
AIDS Office Research Section  
San Francisco Bay Clinical Trial Unit  
December 01, 2014 to November 30, 2015  
Monthly Expenditure and Projection Report

Dept / Div: HPH-03  
Fund Group: 2S/CHS/GNC  
Index Code: HCHVRSRCHGR  
Grant Code: hcd119  
Grant Detail: 1500

\$183,500 SALARY CAPS PER NIH GUIDES eff 01.11.15

BUDGET SUMMARY

A & B.	TOTAL PERSONNEL (SALARIES & FRINGE)	178,272
C.	TRAVEL	0
D.	EQUIPMENT	0
E.	MATERIALS AND SUPPLIES	0
F.	CONTRACT / MOU	0
G.	OTHER	0
	DIRECT COSTS	178,272
H.	INDIRECT COSTS (24.03% of salaries)	32,953
	TOTAL BUDGET	211,225
	AWARD	211,225
	SURPLUS/(DEFICIT)	(0)



San Francisco Department of Public Health (SFPDH)  
AIDS Office  
HIV Research Section

San Francisco Bay Clinical Trails

**BUDGET JUSTIFICATION**  
December 01, 2014- November 30, 2015

**A. PERSONNEL**  
**B. MANDATORY FRINGE**

1. 0943 – Manager VIII (HIV Bridge Director): Susan Buchbinder

Annual Salary  $\$181,500 \times 0.20$  FTE for 12 month =  $\$36,300$   
Mandatory Fringe Benefits (@ 30%) =  $\$10,890$                        $\$47,190$

Dr. Buchbinder serves as the Director of Bridge HIV. She has been the PI of the previous San Francisco Department of Public Health CTU, which is now affiliated with HVTN, HPTN, and MTN. She helps direct the HVTN (through the Executive Management Team) and the HPTN (by co-chairing the Integrated Strategies Working Group). Dr. Buchbinder will be PI of the SFBay CTU with Dr. Diane Havlir, as well as being the Leader of the Bridge HIV CRS. Dr. Buchbinder will be responsible for the overall scientific leadership of the CTU and Bridge HIV CRS, and will prioritize research efforts. She will have final decision-making authority for the CRS; she and Dr. Havlir will share decision making authority for the CTU. She will oversee study implementation at the CRS, ensuring that Division Directors have the resources and skills needed to successfully carry out their protocols, and provide guidance and mentorship to them. She will lead manuscript development at the site, assisting in research design and analysis, presentation and publication of data. She will be the primary liaison to the HVTN, HPTN, and MTN. Dr. Buchbinder will provide input into local study operations including recruitment strategies, decisions about enrollment of potential study volunteers, evaluation of AEs, and quality management issues (including review of study records at the initiation of study protocols). She will review all SAEs and provide clinical cross-coverage for all HVTN study participants. She will continue to serve on the HVTN Executive Management Team, chair the HVTN Efficacy Trials Design Working Group and Investigators Group, and serve on a number of committees and working groups. She will continue to co-chair the HPTN Integrated Strategies Working Group and serve on HPTN committees. She will also chair protocols for all Networks with which she is affiliated.

2. 2232 – Sr. Physician Specialist: Albert Liu, MD  
Annual Salary  $\$181,500 \times 0.16$  FTE for 12 month =  $\$29,040$   
Mandatory Fringe Benefits (@ 30%) =  $\$8,712$                        $\$37,752$

2232 – Sr. Physician Specialist: Albert Liu, MD  
Annual Salary  $\$183,500 \times 0.29135$  FTE for 12 month =  $\$53,463$

Mandatory Fringe Benefits (@ 30%) = \$16,038 \$69,501

2232 – Sr. Physician Specialist: Albert Liu, MD  
Annual Salary \$183,500 x 0.10 FTE for 8 month = \$12,220  
Mandatory Fringe Benefits (@ 30%) = \$3,666 \$15,886

Dr. Liu will co-chair the SFBay CTU Operations Steering Committee and be a major contributor to HPTN and MTN. He will also serve as Co-Leader of the Bridge HIV CRS, providing overarching leadership and mentorship to all of the teams. He will directly oversee all PrEP and microbicide trials conducted at Bridge HIV, including their regulatory and laboratory components, and directly supervise the clinical staff and Study Coordinator. Dr. Liu will be responsible for the overall scientific, operational and administrative aspects of the demonstration project. As the lead investigator of the San Francisco site, he will oversee overall study implementation at this site and will be responsible for study enrollment and retention, data collection, evaluation and reporting of AEs, clinical management of study participants, and quality management. Also, along with the protocol co-chairs, he will have responsibility for achieving the overall specific aims of the project, for maintaining the proposed project schedule, ensuring quality control over all aspects of this project, and data analyses and publication of results.

3. 2233 – Supervising Physician Specialist: Willi McFarland, MD  
Annual Salary \$183,500 x 0.10 FTE for 4 month = \$6,110  
Mandatory Fringe Benefits (@ 30%) = \$1,833 \$7,943

Willi McFarland, MD, PhD, MPH (co-Investigator) is the Director of the Center for Public Health Research (CPHR) at the San Francisco Department of Public Health and Professor of Epidemiology and Biostatistics at the University of California San Francisco (UCSF). Dr. McFarland has over 20-years' experience in sampling and recruiting hidden and hard-to-reach populations for HIV epidemiology, surveillance, and prevention research, including over 10-years' experience with respondent-driven sampling (RDS), and 11 years of experience working in Brazil. He has also been PI for several studies of transgendered persons, including a current NIH-funded study on new methods for probability-based sampling of transmen (R21HD071765). For the current application, Dr. McFarland will provide technical expertise and training for the implementation of RDS among transwomen in Rio de Janeiro, Brazil. He will assist with the formative assessment phase to ensure that the theoretical underpinnings of RDS are met in the study population and context, standardize the procedures for implementation, monitor data quality, and assist with the specialized analyses RDS requires. Dr. McFarland will also coordinate measures and methods with the Brazilian National AIDS Program.

Total Salaries	\$137,133
Total Fringe	\$41,139
<b>TOTAL PERSONNEL:</b>	<b>\$178,272</b>

C.	TRAVEL	\$0
D.	EQUIPMENT	\$0
E.	SUPPLIES	\$0
F.	CONTRACTUAL	\$0
G.	OTHER	\$0
	TOTAL DIRECT COSTS	\$178,272
H.	INDIRECT COSTS (24.03% of Salaries)	\$32,953
	TOTAL BUDGET:	\$211,225



12801 Crossroads Parkway South, Suite 200 City of Industry, CA 91746 P: 800.201.7320 F: 562.692.6950 www.phfe.org

Public Health  
Foundation  
Enterprises

SUBCONTRACT AMENDMENT BETWEEN  
PUBLIC HEALTH FOUNDATION ENTERPRISES, INC.  
AND  
CITY AND COUNTY OF SAN FRANCISCO

Subcontract Amendment 1  
0325.015.001  
SF Bay Area CTU

Article 4 – Payment for Services:

The maximum amount payable shall not exceed \$211,225. This is an increase of \$110,582 over the budget in the executed agreement dated December 1, 2014. This increase is reflected in the attached revised Exhibits B.

Exhibit D – Form of Invoice:

Final invoices must be signed, marked "Final," and have the statement, "This final invoice represents that all deliverables have been met."

All other terms and conditions of this agreement remain in full force and effect.

Authorized signatures completing Subcontract Amendment 1 are provided below.

For Public Health Foundation Enterprises, Inc.:

DocuSigned by: <i>Peter Dale</i>	4/9/2015
<hr/> Peter Dale, Director, Contract and Grant Management	Date

For the City and County of San Francisco:

<i>Tomas Aragón</i>	4/7/15
<hr/> Tomas Aragón, Director, Population Health Division	Date



Exhibit B: Budget B

PrEP Demo 0325.015.903	Principal Investigator/Program Director (Last, first, middle):	Buchbinder, Susan
	FROM	THROUGH
	12/1/2014	11/30/15
<b>DETAILED BUDGET FOR NEXT BUDGET PERIOD - DIRECT COSTS ONLY</b>	GRANT NUMBER	
	UM1AI069496	

List PERSONNEL (Applicant organization only)  
 Use Cal, Acad, or Summer to Enter Months Devoted to Project  
 Enter Dollar Amounts Requested (omit cents) for Salary Requested and Fringe Benefits

NAME	ROLE ON PROJECT	Cal. Mnths	Acad. Mnths	Summ. Mnths	SALARY REQUESTED	FRINGE BENEFITS	TOTAL
Albert Liu	Protocol Chair	3.50			53,463	16,039	69,501
					53,463	16,039	69,501
CONSULTANT COSTS							
EQUIPMENT							
SUPPLIES							
Clinical/Lab Supplies							
							0
TRAVEL							
Domestic Conference for 2 Investigators							
PATIENT CARE COSTS							
INPATIENT							
OUTPATIENT							
ALTERATIONS AND RENOVATIONS							
OTHER EXPENSES							
							0
<b>SUBTOTAL DIRECT COST FOR NEXT BUDGET PERIOD</b>							<b>69,501</b>
CONSORTIUM/CONTRACTUAL COSTS					DIRECT COSTS		0
CONSORTIUM/CONTRACTUAL COSTS					SFDPH Indirects 24.03% of Salary		12,847
<b>TOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD</b>							<b>82,348</b>

Exhibit B: Budget C

Brazil 0325.015.908	Principal Investigator/Program Director (Last, first, middle):	Buchbinder, Susan
FROM		THROUGH
12/1/2014		11/30/15
DETAILED BUDGET FOR NEXT BUDGET PERIOD - DIRECT COSTS ONLY		GRANT NUMBER
		UM1A1069496

List PERSONNEL (Applicant organization only)  
 Use Cal, Acad, or Summer to Enter Months Devoted to Project  
 Enter Dollar Amounts Requested (omit cents) for Salary Requested and Fringe Benefits

NAME	ROLE ON PROJECT	Cal. Mnths	Acad. Mnths	Summ. Mnths	SALARY REQUESTED	FRINGE BENEFITS	TOTAL
Albert Liu	co-Investigator	0.80	10% for 8 months		12,220	3,666	15,886
Willie McFarland	co-Investigator	0.40	10% for 4 months		6,110	1,833	7,943

Project Begins 4.1.15

NAME	ROLE ON PROJECT	Cal. Mnths	Acad. Mnths	Summ. Mnths	SALARY REQUESTED	FRINGE BENEFITS	TOTAL
					18,330	5,499	23,829

CONSULTANT COSTS		
EQUIPMENT		0
SUPPLIES Clinical/Lab Supplies		0
TRAVEL Domestic Conference for 2 Investigators		
PATIENT CARE COSTS	INPATIENT	
	OUTPATIENT	
ALTERATIONS AND RENOVATIONS		
OTHER EXPENSES		0
<b>SUBTOTAL DIRECT COST FOR NEXT BUDGET PERIOD</b>		<b>23,829</b>
CONSORTIUM/CONTRACTUAL COSTS	DIRECT COSTS	0
CONSORTIUM/CONTRACTUAL COSTS	SFDPH Indirects 24.03% of Salary	4,405
<b>TOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD</b>		<b>28,234</b>



Public Health Foundation Enterprises  
A 501 (c) 3 Nonprofit Organization

12801 Crossroads Parkway South, Suite 200 City of Industry, CA 91746 P: 800.201.7320 F: 562.692.6950 www.phfe.org

**[SUBCONTRACT/SUBAWARD] AGREEMENT BETWEEN  
PUBLIC HEALTH FOUNDATION ENTERPRISES, INC.**

**AND**

THE CITY AND COUNTY OF SAN FRANCISCO

**[SUBCONTRACTOR/SUBAWARDEE NAME]**

This [Subcontract/Sub-Award] Agreement (this "Agreement") is made and entered into as of December 1, 2014 by and between PUBLIC HEALTH FOUNDATION ENTERPRISES, INC., a 501(c)(3) California nonprofit corporation (hereinafter referred to as "PHFE"), and the party identified in Section 1 below (hereinafter be referred to as "Subcontractor/Subawardee").

**RECITALS**

A. PHFE has been granted an award by National Institutes of Health (the "Funding Agency"), under contract number 5UM1AI069496-09 (the "Funding Award Agreement") under which PHFE and its subcontractors and subawardees will See Exhibit A (the "Program");

B. Subcontractor/Subawardee has expertise in the areas of See Exhibit A, which expertise can assist PHFE to perform its obligations under the Funding Award Agreement; and

C. PHFE desires to engage the services of Subcontractor/Subawardee to assist PHFE in the performance of certain of its obligations under the Funding Award Agreement as set forth herein.

**AGREEMENT**

**1. IDENTITIES OF PARTIES.**

**SUBCONTRACTOR/SUBAWARDEE:** Please complete:

Legal Name of Subcontractor/Subawardee: City and County of San Francisco

DBA of Subcontractor/Subawardee: SFDPH

Type of Entity:      Sole Proprietorship      Partnership  
                                 Corporation                      Limited Liability Company

State of Organization (if an entity): California



Address: 101 Grove St, Rm 402

City/State/Zip: San Francisco, CA 94102

Business Telephone: (415) 554-2778

Social Security or Employer Identification Number:

License Number and Expiration Date, if any: 94-6000417

Email Address: sajid.shaik@sfdph.org

Name of Principal Investigator/Project Coordinator: Susan Buchbinder

Phone Number of Principal Investigator/Project Coordinator: (415) 437-7479

Is Subcontractor/Subawardee required to file a Single Audit with the Federal Government? (Required for parties who receive Federal funds in the aggregate amount of \$500,000 or more): Please complete:

Yes       No

If yes, has Subcontractor/Subawardee filed the required Single Audit?

Yes       No

(If yes, submit copy to PHFE prior to signing this Agreement)

Download A-133 at <http://sfcontroller.org/index.aspx?page=402>

**PHFE:**

Public Health Foundation Enterprises, Inc.  
12801 Crossroads Parkway South, Suite 200  
City of Industry, CA, 91746-3505  
Main Telephone Number (562) 699-7320

Program Name: SF Bay Clinical Trials Unit

Program/CID #: 0325.015.001 CFDA: 93.855 (One per agreement)

Contracts Manager Name: Shane Vigil

Contracts Manager Email Address: svigil@phfe.org

Program Director Name: Susan Buchbinder Telephone Number: (415) 437-7407

Program Director Email: Susan.Buchbinder@sfdph.org

Initials  
PD  
PHFE  
BS  
Subcontractor/Subawardee

2. SCOPE OF SERVICES.

(a) Services. Subcontractor/Subawardee shall perform the services, duties and obligations set forth in the Statement of Work ("SOW") attached as Exhibit A hereto, which is made a part hereof and incorporated herein by reference (the "Services"). The Services relate to Sections Exhibit C and n/a of the Funding Award Agreement. Subcontractor/Subawardee shall perform the Services in accordance with the specifications, timetables and requirements set forth in the SOW and this Agreement. PHFE may, in its discretion, provide to Subcontractor/Subawardee a copy of the Funding Award Agreement or the relevant sections thereof. If Subcontractor/Subawardee is provided with a copy of the Funding Award Agreement or the relevant sections thereof, Subcontractor/Subawardee shall carefully review them and shall perform the Services in accordance with the specifications, timetables and requirements set forth therein.

(b) Location(s) of Services. Subcontractor/Subawardee shall perform the Services at the following location(s): Please complete:

25 Van Ness Av Ste 100  
San Francisco, CA 94102

(c) Subcontractor/Subawardee Principal Investigator/Project Coordinator. Subcontractor/Subawardee shall appoint the Principal Investigator/Project Coordinator (the "PI") identified above to be primary point of contact with PHFE and the Funding Agency with respect to the Services and to have primary responsibility within Subcontractor's/Subawardee's organization for the performance of the (technical or programmatic) aspects of the Services. Subcontractor/Subawardee shall not replace or reassign the PI without PHFE's and the Funding Agency's prior written approval.

(d) PHFE Project Director. The PHFE Project Director identified above shall be primarily responsible on behalf of PHFE for the overall direction of the Services, including review and approval of Subcontractor's/Subawardee's performance of the Services. PHFE will notify Subcontractor/Subawardee if PHFE replaces or reassigns such Project Director.

(e) Performance Reporting. If requested by PHFE or the Funding Agency, Subcontractor/Subawardee shall submit a final technical or performance report, annual performance report, and quarterly performance reports. The final report shall be due 30 days after expiration or termination of this Agreement; annual reports and quarterly reports shall be due 30 days after the reporting period. Subcontractor/Subawardee shall also provide any other reports as may be requested by PHFE. Performance reports shall include a comparison of actual accomplishments with goals and objectives established for the period, findings of the PI, or both, as requested by PHFE. Where possible, quantitative output data should be related to cost data for computation of unit costs. Other pertinent information will include, when appropriate, the reasons why established goals were not met and an analysis. Subcontractor/Subawardee shall immediately

Initials  
PHFE PD  
Subcontractor/Subawardee SS



that all employment related decisions are made in conformance with all such statutes, laws, rules and regulations; and

(iv) unless it is exempt from doing so, comply with 45 CFR Part 76, Appendix B-Certification Regarding Debarment, Suspension, and Ineligibility, Voluntary Exclusion-Lower Tier Covered Transactions.

(d) HIPAA Business Associate Agreement. If the Health Insurance Portability and Accountability Act of 1996, as amended ("HIPAA") is applicable to the Services, Subcontractor/Subawardee shall execute and deliver PHFE's standard Business Associate Agreement as required by HIPAA.

(e) Lower-tier Subcontractors/Subawardees. Subcontractor/Subawardee shall incorporate all of the terms and conditions of this Agreement into all lower-tier subcontracts that Subcontractor/Subawardee may enter into in connection with this Agreement, and shall ensure that all such lower-tier subcontractors/subawardees and their personnel comply with all of the requirements of this Agreement applicable to Subcontractor/Subawardee, and all of the rules, requirements and restrictions set forth in the Funding Award Agreement, including the Flow Down Provisions, that are applicable to such lower-tier subcontractors'/subawardees' activities.

#### 4. PAYMENT FOR SERVICES

(a) Budget. The total compensation and reimbursements payable to Subcontractor/Subawardee hereunder shall be as set forth in the detailed budget for the Services attached hereto as Exhibit B (the "Budget"), which is made a part hereof and incorporated herein by reference, which Budget is as set forth in the Funding Award Agreement. The maximum amount payable to Subcontractor/Subawardee hereunder shall not exceed the maximum amount set forth in the Budget.

(b) Must Stay Within Budget Time Periods. Subcontractor/Subawardee shall be compensated only for Services actually performed by Subcontractor/Subawardee and within the appropriate time period set forth in the Budget.

(c) Approval of Services by PHFE. All Services must be completed to the satisfaction of PHFE in order to be entitled to payment hereunder.

(d) Funds Available to PHFE. PHFE shall not be obligated to make payment under this Agreement unless the corresponding funds are disbursed to PHFE under the Funding Award Agreement. In the event that PHFE has made payment to Subcontractor/Subawardee under this Agreement and PHFE subsequently does not receive from the Funding Agency for any reason the corresponding payment for the Services performed by Subcontractor/Subawardee or expenses incurred by Subcontractor/Subawardee, then Subcontractor/Subawardee shall refund such payment to PHFE within ten (10) days after written notice from PHFE.













(d) No Liens. Subcontractor/Subawardee shall deliver all Work Product to PHFE free and clear of any and all claims, rights and encumbrances of third parties.

(e) Assignment Documents. Subcontractor/Subawardee will cooperate with PHFE, with PHFE's approval and at PHFE's expense, in obtaining patent, copyright, trademark or other statutory protections for the Work Product in each country in which one or more is sold, distributed or licensed, and in taking any enforcement action, including any public or private prosecution, to protect PHFE's intellectual property rights in or to the Work Product. Subcontractor/Subawardee hereby grants PHFE the exclusive right, and appoints PHFE as attorney-in-fact, to execute and prosecute in Subcontractor's/Subawardee's name as author or inventor or in PHFE's name as assignee, any application for registration or recordation of any copyright, trademark, patent or other right in or to the Work Product, and to undertake any enforcement action with respect to any Work Product. With PHFE's approval and at PHFE's expense, Subcontractor/Subawardee will execute such other documents of registration and recordation as may be necessary to perfect in PHFE, or protect, the rights assigned to PHFE hereunder in each country in which PHFE reasonably determines to be prudent.

(f) No Infringement. Subcontractor/Subawardee represents and warrants that any Work Product delivered to PHFE hereunder will be developed by Subcontractor/Subawardee and shall not infringe or violate any patents, copyrights, trademarks, trade secrets or other proprietary rights of any third party.

(g) No Harmful Code. With respect to the website and any computer programs or software code ("Software") included in the Services hereunder, Subcontractor/Subawardee represents and warrants that: (i) the Software and its media shall contain no computer instructions or inappropriate functions whose purpose or result is to disrupt, damage or interfere with PHFE's or its affiliates' or their customers' use of or access to the Software or any of their data, programs or computer or telecommunications facilities and (ii) unless expressly authorized in writing by PHFE, such Software shall not contain any mechanism which electronically notifies Subcontractor/Subawardee of any fact or event, nor contain any key, node lock, time-out, logic bomb or other function, implemented by any means, which may restrict PHFE's or its affiliates' or customers' use of or access to the Software or any other programs, data or equipment.

(h) Rights of Funding Agency and Federal Government. All rights to the Work Product assigned or granted to PHFE hereunder shall be subject to any rights of the Funding Agency under the Funding Award Agreement and any rights of the United States Federal Government under applicable laws and regulations.

## 10. PUBLICATIONS

(a) Right to Publish Works. Subcontractor/Subawardee may, with PHFE's and the Funding Agency's prior written consent, publish articles written by Subcontractor/Subawardee in connection with the Services performed by Subcontractor/Subawardee hereunder. Subcontractor/Subawardee shall submit all such articles for review by PHFE and the Funding Agency at least 60 days prior to the proposed publication date.







and consistent with the laws of the State of California without giving effect to its conflicts of laws principals. Such laws shall apply in all respects, including statutes of limitation, to any disputes or controversies arising out of or pertaining to this Agreement. The sole, exclusive and proper venue for any proceedings brought to interpret or enforce this Agreement or to obtain a declaration of the rights of the parties hereunder shall be Los Angeles County, California. Each of the parties hereto submits to the exclusive personal jurisdiction of the courts located in Los Angeles County, California and waives any defense of forum non conveniens.

(c) Equitable Relief. In light of the irreparable harm to PHFE that a breach by Subcontractor/Subawardee of Sections 9, 10, 13 and 14 of this Agreement would cause, in addition to other remedies set forth in this Agreement and other relief for violations of this Agreement, PHFE shall be entitled to enjoin Subcontractor/Subawardee from any breach or threatened breach of such Sections, to the extent permitted by law and without bond.

(d) Binding Agreement. All terms, conditions and covenants to be observed and performed by the parties hereto shall be applicable to and binding upon their respective agents, employees, heirs, executors, administrators, affiliates, subsidiaries, associates, employees, successors and assigns.

(e) Captions. All captions (section headings) set forth herein are inserted only as a matter of convenience and for reference, and shall not affect the interpretation of this Agreement.

(f) Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of which, when taken together, shall constitute one and the same document.

(g) Additional Documents. The parties hereto each agree that they shall execute and, if appropriate, acknowledge any and all additional and other documents, instruments and writings which may be reasonably requested by the other party in order to fully carry out the intent and purpose of this Agreement.

(h) Attorneys' Fees; Costs. In the event that any suit in law or equity, arbitration or other formal proceeding is instituted by any party to enforce or interpret any part of this Agreement, or to recover damages for breach thereof, the prevailing party shall, in addition to any such other relief available to such party, be entitled to recover costs of suit incurred therein, and to also recover as an element of such costs (but not as damages) reasonable attorneys' fees incurred by such prevailing party.

(i) Entire Agreement. This Agreement, and all documents referred to in it, or incorporated in it, is an integrated document containing and expressing all terms, covenants, conditions, warranties and agreements of the parties relating to the subject matter hereof. No other or prior agreements or understandings, written or oral, pertaining to the same shall be valid or of any force or effect.







consent of the other party. Any attempt to assign this Agreement other than as permitted above shall be null and void.

(r) Signing Person. The individuals signing this Agreement on behalf of an entity represents and warrants that he/she has authority to bind such entity to this Agreement.

[Signatures follow on next page]

The undersigned have caused this Subcontract/Subaward Agreement to be executed as of the date first set forth above:

**PUBLIC HEALTH FOUNDATION ENTERPRISES, INC.**

DocuSigned by:  
Peter Dale  
By: CP32342CDB54420  
Peter D. Dale  
Director, Contract and Grant Management

2/5/2015  
Date

**SUBCONTRACTOR/SUBAWARDEE**

Name: \_\_\_\_\_

2/5/15  
Date

Signature: Tomás Aragón

Tomás J. Aragón, MD, DrPH

Print Name, Title [If any entity]  
Director, Population Health Division (PHD)

EXHIBIT A  
TO SUBCONTRACT/SUBAWARD AGREEMENT

Scope of Work (SOW)

Dr. Buchbinder is Director of Bridge HIV. She has been the PI of the previous San Francisco Department of Public Health CTU, which is now affiliated with HVTN, HPTN, and MTN. She helps direct the HVTN (through the Executive Management Team) and the HPTN (by co-chairing the Integrated Strategies Working Group). Dr. Buchbinder will be PI of the SF Bay CTU with Dr. Diane Havlir, as well as being the Leader of the Bridge HIV CRS. Dr. Buchbinder will be responsible for the overall scientific leadership of the CTU and Bridge HIV CRS, and will prioritize research efforts. She will have final decision-making authority for the CRS; she and Dr. Havlir will share decision-making authority for the CTU. She will oversee study implementation at the CRS, ensuring that Division Directors have the resources and skills needed to successfully carry out their protocols, and provide guidance and mentorship to them. She will lead manuscript development at the site, assisting in research design and analysis, presentation and publication of data. She will be the primary liaison to the HVTN, HPTN, and MTN. Dr. Buchbinder will provide input into local study operations including recruitment strategies, decisions about enrollment of potential study volunteers, evaluation of AEs, and quality management issues (including review of study records at the initiation of study protocols). She will review all SAEs and provide clinical cross-coverage for all HVTN study participants. She will continue to serve on the HVTN Executive Management Team, chair the HVTN Efficacy Trials Design Working Group and Investigators Group, and serve on a number of committees and working groups. She will continue to co-chair the HPTN Integrated Strategies Working Group and serve on HPTN committees. She will also chair protocols for all Networks with which she is affiliated.

Dr. Liu will co-chair the SF Bay CTU Operations Steering Committee and be a major contributor to HPTN and MTN. He will also serve as Co-Leader of the Bridge HIV CRS, providing overarching leadership and mentorship to all of the teams. He will directly oversee all PrEP and microbicide trials conducted at Bridge HIV, including their regulatory and laboratory components, and directly supervise the clinical staff and Study Coordinator. Dr. Liu will be responsible for the overall scientific, operational and administrative aspects of the upcoming PrEP demonstration project. As the lead investigator of the San Francisco site, he will oversee overall study implementation at this site and will be responsible for study enrollment and retention, data collection, evaluation and reporting of AEs, clinical management of study participants, and quality management. Also, along with the protocol co-chairs, he will have responsibility for achieving the overall specific aims of the project, for maintaining the proposed project schedule, ensuring quality control over all aspects of this project, and data analyses and publication of results.

EXHIBIT B  
TO SUBCONTRACT/SUBAWARD AGREEMENT

Budget

Budget follows on next page



EXHIBIT C  
TO SUBCONTRACT/SUBAWARD AGREEMENT  
FLOW DOWN PROVISIONS

See following pages.

Initials  
PHFE PD  
Subcontractor/Subawardee SS

Notice of Award



Multi-Component Research Project Co-op Agreements Issue Date: 11/17/2014  
Department of Health and Human Services  
National Institutes of Health  
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES



Grant Number: 5UM1AI069496-09  
FAIN: UM1AI069496

Principal Investigator(s):  
Susan Buchbinder (contact), MD  
Diane V Havlir, MD

Project Title: San Francisco Bay Clinical Trials Unit

PETER DALE  
PUBLIC HEALTH FOUNDATION ENTERPRISES, INC  
12801 CROSSROADS PARKWAY SOUTH  
SUITE 200  
CITY OF INDUSTRY, CA 917466050

Award e-mailed to: pdale@phfe.org

Budget Period: 12/01/2014 – 11/30/2015  
Project Period: 03/02/2007 – 11/30/2020

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$1,264,362 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to PUBLIC HEALTH FOUNDATION ENTERPRISES in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number UM1AI069496. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Michael W. Fato  
Grants Management Officer  
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows



**SECTION I – AWARD DATA – 5UM1AI069496-09**

**Award Calculation (U.S. Dollars)**

Salaries and Wages	\$420,554
Fringe Benefits	\$126,166
Supplies	\$5,094
Travel Costs	\$12,852
Other Costs	\$10,000
Consortium/Contractual Cost	\$627,632

Federal Direct Costs	\$1,202,298
Federal F&A Costs	\$62,064
Approved Budget	\$1,264,362
Federal Share	\$1,264,362
<b>TOTAL FEDERAL AWARD AMOUNT</b>	<b>\$1,264,362</b>

**AMOUNT OF THIS ACTION (FEDERAL SHARE) \$1,264,362**

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
9	\$1,264,362	\$1,264,362
10	\$1,264,362	\$1,264,362
11	\$1,264,362	\$1,264,362
12	\$1,264,362	\$1,264,362
13	\$1,264,362	\$1,264,362
14	\$1,264,362	\$1,264,362

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**Fiscal Information:**

CFDA Number: 93.855  
 EIN: 1952557063A1  
 Document Number: UAI069496B

PMS Account Type: P (Subaccount)  
 Fiscal Year: 2015

IC	CAN	2015	2016	2017	2018	2019	2020
AI	8472297	\$1,264,362	\$1,264,362	\$1,264,362	\$1,264,362	\$1,264,362	\$1,264,362

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**NIH Administrative Data:**

PCC: A28Z / OC: 414P / Released: FATOM 11/14/2014  
 Award Processed: 05/08/2014 01:52:21 PM

**SECTION II – PAYMENT/HOTLINE INFORMATION – 5UM1AI069496-09**

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

**SECTION III – TERMS AND CONDITIONS – 5UM1AI069496-09**

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.

- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 74 or 45 CFR Part 92 as applicable.
- d. The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the Central Contractor Registration. Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) UM1A1069496. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

This award is not subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award provides support for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register "applicable clinical trials" on the [ClinicalTrials.gov](http://ClinicalTrials.gov) Protocol Registration System Information Website. NIH encourages registration of all trials whether required under the law or not. For more information, see [http://grants.nih.gov/ClinicalTrials\\_fdaaa/](http://grants.nih.gov/ClinicalTrials_fdaaa/)

This award provides support for one or more NIH defined Phase III Clinical Trials. The NIH Policy for research supported as an NIH Phase III Clinical Trial has been amended in Section II.B. of the NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research – Amended October 2001 (see [http://grants.nih.gov/grants/funding/women\\_min/guidelines\\_amended\\_10\\_2001.htm](http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm)).

A description of plans to conduct analyses, as appropriate, by sex/gender and racial/ethnic groups must be included in clinical trial protocols. Cumulative subject accrual and progress in conducting subset analyses must be reported to NIH in the annual Progress Reports. Final analyses of sex/gender and racial/ethnic differences must be reported in the required Final Progress Report or Competitive Renewal Applications (or Contract Renewals/Extensions) as stated in Section II.B. of the Guidelines.

**Treatment of Program Income:**  
Additional Costs

---

**SECTION IV – AI Special Terms and Conditions – 5UM1A1069496-09**

This award provides core funding for the following Clinical Research Sites (CRS) in support of the following Networks:

HPTN, HVTN, MTN  
ACTG

Bridge CRS  
UCSF CRS

Page-4

Continued support will be based on a satisfactory evaluation at the end of a time period designated as appropriate by each Network.

Satisfactory evaluation will be based on meeting Network and NIAID/DAIDS performance standards by the end of each performance period.

The Network will assist sites to address performance or accrual deficiencies, and negotiate deadlines for demonstrating improvement as necessary

IF ANY CRS IS UNABLE TO MEET THE REQUIREMENTS OF THE NETWORK LEADERSHIP AND OPERATIONS CENTER (LOC) AND NIAID/DAIDS BY ITS NEGOTIATED DEADLINE, FUNDING MAY BE WITHDRAWN AND A PLAN TO PHASE-OUT THE CRS WILL BE ESTABLISHED.

If it is determined by NIAID/DAIDS in collaboration with the Network LOC that the CTU and/or affiliated CRS has performance or other issues, the grantee will first be notified in writing by the Network LOC. A plan of action will be developed by the Network LOC in conjunction with DAIDS including expectations for corrective actions and timelines for implementing such corrective actions.

**PROTOCOL SUPPORT**

Additional funding for protocol activity will be provided by the respective Network LOC(s) through sub-contracts.

**KEY PERSONNEL**

The following key personnel (as defined by NIAID/DAIDS) need prior NIAID/DAIDS approval before they may be replaced on the grant (**Susan Buchbinder and Diane Havlir, CTU PIs and CRS Leaders for Bridge CRS and UCSF CRS respectively**). Prior approval will be granted via revised NoA.

In addition, changes to the individuals who occupy the following positions: CTU Coordinator, each CRS Coordinator, and each Pharmacist(s) of Record must also be approved by DAIDS; however, these changes will not require a revised Notice of Award.

The grantee is required to follow any applicable Network policies and procedures for obtaining prior approval for changes in these positions.

All components of the CTU are required to comply with NIH, NIAID, and DAIDS policies & procedures, including NIAID Clinical Terms of Award; and affiliated Network policies & procedures. See DAIDS Clinical Research Policies and Standard Procedures located at:

<http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Pages/Default.aspx>

\*\*\*\*\*  
This award includes funds awarded for consortium activity with the University of California, San Francisco in the amount of \$515,813 (\$384,935 direct costs + \$130,878 facilities and administrative costs).

This award includes funds awarded for consortium activity with the San Francisco Department of Public Health in the amount of \$111,819 (\$94,380 direct costs + \$17,439 facilities and administrative costs).

Consortiums are to be established and administered as described in the NIH Grants Policy Statement (NIH GPS). The referenced section of the NIH Grants Policy Statement is available at [http://grants.nih.gov/grants/policy/nihgps\\_2013/nihgps\\_ch15.htm#\\_Toc271265264](http://grants.nih.gov/grants/policy/nihgps_2013/nihgps_ch15.htm#_Toc271265264).

\*\*\*\*\*  
This award is issued as a Cooperative Agreement, a financial assistance mechanism in which substantial NIH scientific and/or programmatic involvement is anticipated in the performance of the activity. This award is subject to the Terms and Conditions of Award as set forth in Section VI: Award Administrative Information of RFA AI-12-018, "Clinical Trials Units for NIAID Networks (UM1)," release date 01/27/2012, which are hereby incorporated by reference as special terms and conditions of this award.

This RFA may be accessed at: <http://grants.nih.gov/grants/guide/index.html>

**STAFF CONTACTS**

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

**Grants Management Specialist:** Julia L. Shriner  
**Email:** julia.shriner@nih.gov **Phone:** 240-669-2972 **Fax:** 301-493-0597

**Program Official:** Patricia L. Jones  
**Email:** jonespl@mail.nih.gov **Phone:** 240-292-4851

**SPREADSHEET SUMMARY**  
**GRANT NUMBER:** 5UM1AI069496-09

**INSTITUTION:** PUBLIC HEALTH FOUNDATION ENTERPRISES

Budget	Year 9	Year 10	Year 11	Year 12	Year 13	Year 14
Salaries and Wages	\$420,554	\$420,554	\$420,554	\$420,554	\$420,554	\$420,554
Fringe Benefits	\$126,166	\$126,166	\$126,166	\$126,166	\$126,166	\$126,166
Supplies	\$5,094	\$5,094	\$5,094	\$5,094	\$5,094	\$5,094
Travel Costs	\$12,852	\$12,852	\$12,852	\$12,852	\$12,852	\$12,852
Other Costs	\$10,000	\$10,000	\$10,000	\$10,000	\$10,000	\$10,000
Consortium/Contractual Cost	\$627,632	\$627,632	\$627,632	\$627,632	\$627,632	\$627,632
TOTAL FEDERAL DC	\$1,202,298	\$1,202,298	\$1,202,298	\$1,202,298	\$1,202,298	\$1,202,298
TOTAL FEDERAL F&A	\$62,064	\$62,064	\$62,064	\$62,064	\$62,064	\$62,064
TOTAL COST	\$1,264,362	\$1,264,362	\$1,264,362	\$1,264,362	\$1,264,362	\$1,264,362

Facilities and Administrative Costs	Year 9	Year 10	Year 11	Year 12	Year 13	Year 14
F&A Cost Rate 1	10.8%	10.8%	10.8%	10.8%	10.8%	10.8%
F&A Cost Base 1	\$574,666	\$574,666	\$574,666	\$574,666	\$574,666	\$574,666
F&A Costs 1	\$62,064	\$62,064	\$62,064	\$62,064	\$62,064	\$62,064



# Introduction Form

By a Member of the Board of Supervisors or the Mayor

Time stamp  
or meeting date

I hereby submit the following item for introduction (select only one):

- 1. For reference to Committee. (An Ordinance, Resolution, Motion, or Charter Amendment)
- 2. Request for next printed agenda Without Reference to Committee.
- 3. Request for hearing on a subject matter at Committee.
- 4. Request for letter beginning "Supervisor [ ] inquires"
- 5. City Attorney request.
- 6. Call File No. [ ] from Committee.
- 7. Budget Analyst request (attach written motion).
- 8. Substitute Legislation File No. [ ]
- 9. Reactivate File No. [ ]
- 10. Question(s) submitted for Mayoral Appearance before the BOS on [ ]

Please check the appropriate boxes. The proposed legislation should be forwarded to the following:

- Small Business Commission       Youth Commission       Ethics Commission
- Planning Commission       Building Inspection Commission

**Note: For the Imperative Agenda (a resolution not on the printed agenda), use a Imperative Form.**

**Sponsor(s):**

Supervisor Wiener


**Subject:**

Accept and Expend Grant- San Francisco Bay Clinical Trials Unit - \$211,225

**The text is listed below or attached:**

Resolution authorizing the San Francisco Department of Public Health to retroactively accept and expend a grant in the amount of \$211,225 from Public Health Foundation Enterprises to participate in a program entitled San Francisco Bay Clinical Trials Unit for the period of December 1, 2014, through November 30, 2015.

Signature of Sponsoring Supervisor:



For Clerk's Use Only: